Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Generally healthy female \> 40 years of age with a body mass index (BMI) ≤ 40;~2. Has undergone menopause defined as any of the following:~   At least 12 months of spontaneous amenorrhea; or At least 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels \> 40 mIU/mL; or At least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy);~3. Experience a minimum of 7 moderate to severe hot flushes per day or 50 moderate to severe hot flushes per week~Exclusion Criteria:~1. Resting systolic blood pressure (SBP) \<110 mmHg, resting diastolic blood pressure (DBP) \<50 mm Hg, or a resting heart rate (HR) \<60 beats per minute while awake;~2. Subjects with pre-existing orthostatic hypotension at Screening;~3. Use of oral estrogen-, progestin-, androgen-, or selective estrogen receptor modifier (SERM) -containing drug products within 8 weeks prior to Screening; use of transdermal hormone products within 8 weeks prior to Screening; use of vaginal hormone products (rings, creams, gels) within 4 weeks prior to Screening; use of intrauterine progestins within 8 weeks prior to Screening; use of progestin implants or estrogen injectables within 3 months prior to Screening; use of estrogen pellet or progestin injectables within 6 months prior to Screening;~4. History of daily usage (at least 28 days/month) of either of the following during the month prior to initiation of Screening: Antihypertensives or Prophylactic antimigraine medications

- Gender: FEMALE
- Minimum Age: 41 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AR08 0.5 mg/day (Type: EXPERIMENTAL): AR08 QD oral dosing for 14 weeks
- AR08 1.0 mg/day (Type: EXPERIMENTAL): AR08 QD oral dosing for 14 weeks
- AR08 2.0 mg/day (Type: EXPERIMENTAL): AR08 QD oral dosing for 14 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo QD oral dosing for 14 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).